Navigation Links
Cancers in Biological Technology

The World's Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers

... with one goal in mind: to destroy the metastatic cancers from the inside. Guided by nature's own ... in many cancers. By selectively targeting cancers and their associated blood supply, while sparing ... " vigilant ." By taking on a broad spectrum of cancers that are determined to be refractory to standard ...

Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial

... paclitaxel/carboplatin for patients with advanced cancers were presented at the Fifth International Meeting ... those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for ... for patients with head and neck cancers is currently underway in the U.S. Interim results ...

Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon

... death in the US and Europe.(1) However, most cancers of the lower gastrointestinal (GI) tract can be ... percent of polyps and a significant number of cancers can be missed during colonoscopy.(2,3,4) ... colonoscopy missed about one-third of colorectal cancers (CRCs) on the left side of the colon and 40-67 ...

Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic

... therapeutic class can systemically target cancers in a highly selective and potent fashion using ... that is effective even against cancers that are resistant to standard therapies such as ... with immune-stimulatory GM-CSF that destroys cancers by complementary and synergistic mechanisms. ...

Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers

... cancer at ASCO's 2009 Gastrointestinal (GI) cancers Symposium in San Francisco. In February, updated ... will be presented at ASCO's Genitourinary (GU) cancers Symposium in Orlando, Fla. Presentation details are as follows: -- The ASCO 2009 GI cancers Symposium, San Francisco -- Randomized ...

YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE

... Phase III trial of more than 700 patients with cancers of the head and neck. The NCCS stated that it ... patients with locally advanced squamous cell cancers of the head and neck immediately following ... study in locally-advanced head and neck cancers is being conducted by the NCCS in collaboration ...

Interim Report for the Period 1 January - 30 September 2008 (Unaudited)

... year end 2008 and is targeting one of the major cancers addressing a patient population of approximately ... has identified miRNA targets involved in major cancers (lung, colon, breast and ovary cancer) for our ... tests for drug resistance testing in major cancers including colon, lung (NSCLC), ovary and breast, ...

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

... is part of a Phase 2 program in gynaecological cancers for which patient enrolment began in December ... Phase 1 study in various gynaecological cancers were presented at the American Society of ... with LHRH-receptor positive gynaecological cancers were recruited. AEZS-108 was administered ...

Lixte Biotechnology Holdings Announces New Appointment to Board of Directors

... Company is developing new treatments for several cancers for which better treatments are urgently needed. ... has expanded the scope of its program to other cancers of neural tissue (nerve and brain), including ... common cancer of children, and to other common cancers of adults. The program was expanded because each ...

/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/

... RAS pathway. Approximately two thirds of all cancers have an activated RAS pathway, including most ... REOLYSIN(R) that selectively replicates in cancers with an activated RAS pathway resulting from EGFR ... is in the treatment of patients with metastatic cancers including NSCLC who have a mutated K-RAS gene and ...

Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours

... RAS pathway. Approximately two thirds of all cancers have an activated RAS pathway, including most ... REOLYSIN(R) that selectively replicates in cancers with an activated RAS pathway resulting from EGFR ... is in the treatment of patients with metastatic cancers including NSCLC who have a mutated K-RAS gene and ...

Sonus Pharmaceuticals and OncoGenex Technologies to Merge

... Non-Small Cell Lung cancers - - Conference Call to be Held Wednesday, May ... as a therapeutic in a broad number of cancers at different stages and can potentially be ... has the potential to delay disease progression in cancers dependent upon IGF-1 for tumor growth. ...

Oncolytics Biotech Inc. Announces 2008 First Quarter Results

... metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal ... such as head and neck, melanoma, lung and ovarian cancers that are refractory (have not responded) to ... of pharmaceutical products for the treatment of cancers that have not been successfully treated with ...

JCI table of contents: April 22, 2008

... cells of many types of cancer, especially blood cancers such as multiple myeloma, express only one cyclin ... a good approach to treating individuals with cancers characterized by a reliance on just one cyclin D ... D1 and/or cyclin D2 to benefit individuals with cancers characterized by a reliance on either cyclin D1 ...

ARIUS presents new findings for anti-cancer antibody programs at AACR

... of cancer stem cells in a broad range of solid cancers and AML. The first toxicology studies have been ... in in vivo models of pancreatic, breast and AML cancers and treatment led to a decrease in ... activity towards a broad range of high incidence cancers and is highly potent at low dose ...

Gynecologic Oncologist, With Board Certification in GYN Oncology, OB/GYN, and Surgery Offers Women With Cancer the Newest Treatment Frontier: the Surgical Robot

... extensive training in the surgical treatment of cancers of the female reproductive system. The complexity ... That's why women who are treated for gynecologic cancers at The Cancer Center at Hackensack University ... is showing that robotic surgery for gynecologic cancers is at least or more effective than traditional ...

Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers

... for Complex and Rare Cancers. Complex and rare cancers comprise approximately 15 percent of new cancer ... Blue Distinction Centers for Complex and Rare cancers are facilities within participating Blue Cross ... cancer -- gastric cancer -- head and neck cancers -- liver cancer -- ocular melanoma -- ...

AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers

... commenced in its Phase 2 trial in gynaecological cancers for which patient enrolment had begun in December ... Phase 1 study in various gynaecological cancers were presented at the American Society of ... with LHRH-receptor positive gynaecological cancers were recruited. AEZS-108 was administered ...

JCI table of contents: Dec. 3, 2007

... that can prevent and treat UV lightinduced skin cancers has been provided by a new study in a mouse model ... mice already carrying UVB lightinduced skin cancers with CP-31398 reduced tumor growth and volume. ... as STAT3 is persistently activated in 50% of lung cancers known as adenocarcinomas, including those that ...

Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT

... on the discovery of a new biomarker for brain cancers by collaborators at NIH, the company is ... its new compounds against two life- threatening cancers of children, neuroblastoma and medulloblastoma, and against several common cancers of adults in addition to GBM. About the National ...

Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.

... testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that Eamonn P. Hobbs, 51, a member of the ... in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property ...

Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial

... of the trial included those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard ... of REOLYSIN and carboplatin/paclitaxel for patients with head and neck cancers is currently underway in the U.S. About Oncolytics Biotech Inc. ...

Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index

... testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it will be added to the broad-market ... in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property ...

Delcath Enters Agreement to Sell 869,565 Units

... Percutaneous Hepatic Perfusion (PHP(TM)) System for the treatment of cancers of the liver, today announced that it has entered into a definitive ... in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property ...

Delcath Systems Granted Third Orphan Drug Designation

... testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that the United States Food and Drug ... in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property ...

Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... antigen widely expressed on common cancers. MUC1 is over-expressed on many cancers such as lung cancer, breast cancer, prostate cancer and colorectal cancer. ... and regulation of PI-3 kinase is implicated in a large proportion of human cancers including breast, glioma, colon, ovarian, prostate and melanoma, where it ...

Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma

... Percutaneous Hepatic Perfusion (PHP(TM)) System for the treatment of cancers of the liver, announced today that Eric D. Whitman, MD, Director of the ... in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property ...

Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB

... including apparent complete tumor regression, for a wide range of human cancers such as breast cancer, prostate cancer, malignant melanoma, multiple ... of cancer drugs have successfully been launched over the last decade, many cancers still lack an effective therapy. This, together with the fact that many ...

Groundbreaking Research Begins for Pancreatic and Lung Cancers

... and Georgia Tech plan on expanding the collaborative research to lung cancers in April, as well as to prostate and colorectal cancers in the following months. Contact: Lynn Peterson ...

Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial

... in combination with gemcitabine (Gemzar(R)) in patients with advanced cancers including breast, and head and neck. The principal investigators are Dr. ... or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to standard therapy or for which ...

Patent for Making Combination Chemotherapy Work Better

... an improved method of treating lung, brain, pancreatic, breast and colon cancers that are driven by a mutation known as HER1 overexpression (also called ... cells in the S-Phase would provide a way of indefinitely keeping most cancers in check. Tripling the number, while simultaneously preventing tumor ...

Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

... Patients - - Data To Be Presented at ASCO's 2009 Genitourinary cancers Symposium - - Medivation to Host Conference Call and Webcast ... at the American Society of Clinical Oncology's (ASCO) 2009 Genitourinary cancers Symposium in Orlando, Fla. Teleconference/Webcast Details Dr. ...

Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer

... at the American Society of Clinical Oncology's 2009 Genitourinary cancers Symposium - SOUTH SAN FRANCISCO, Calif., Feb. 25 ... the American Society of Clinical Oncology's (ASCO) 2009 Genitourinary cancers Symposium in Orlando, Fla. Picoplatin, the Company's lead product ...

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER

... said David Allan, Chairman and CEO of YM BioSciences. "We have focused on cancers typically treated with radiation-containing regimens because the ... setting in a multinational Phase III trial of more than 700 patients with cancers of the head and neck. The NCCS stated that it selected nimotuzumab because ...

Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point

... Percutaneous Hepatic Perfusion ("PHP") System for the treatment of cancers of the liver, announced today that the first fifty percent (46 of 92) of ... in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property ...

China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits

... potential." Lung cancer is one of the most common cancers in the world and it is the leading cause of cancer death in China. It is ... using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit ...

Genoptix Ranked Ninth Fastest-Growing Company in North America on Deloitte's 2008 Technology Fast 500

... to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Genoptix ... to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in ...

Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer

... ovarian, pancreatic, gastrointestinal, liver, colorectal, and other cancers where the laminin receptor is over-expressed. Its lead product, CYN 101, ... types, including ovarian, pancreatic, GI, liver, colorectal, and other cancers where the laminin receptor is overexpressed. The Company's lead product, ...

Oncolytics Biotech Inc. Announces 2008 Third Quarter Results

... in combination with docetaxel (Taxotere(R)) in patients with advanced cancers including bladder, prostate, lung and upper gastro-intestinal; - ... and docetaxel trial; - The selection of refractory head and neck cancers for the Company's first pivotal trial; - Results of two ...

Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan

... for his work in pancreatic, breast, gastrointestinal, colon, and ovarian cancers and was the first medical oncologist to treat patients with Rexin-G for ... Monitor for the National Surgical Adjuvant Project for Breast and Bowel cancers Project (NSABP) sponsored by the National Cancer Institute. For further ...
Other Contents
(Date:7/25/2014)... WA Nearly 600 scientists from 25 countries ... Genetics Meeting organized by the Genetics Society of ... Washington in Seattle. The conference will feature close ... research results on topics including gene expression and ... emerging technologies, evolution, aging, and a variety of ...
(Date:7/25/2014)... consume the healthcare community and remain priority ... To address the worldwide crisis of obesity ... global leaders in diabetes, epidemiology and public ... and development of diverse intervention programs in ... This book on "Global Health Perspectives in ...
(Date:7/25/2014)... pleiotropic factor characterized by the existence of numerous ... confer to the protein deeply different characteristics. NRG1 ... occurring during development and the different phases occurring ... axon regrowth, remyelination and target reinnervation, Researchers at ... the soluble NRG1 upregulation observed in Schwann cells ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2What constitutes an effective response to the global 'diabesity' tsunami? 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 Drexel University ... D. Weber, MD, MS, FACP, has been appointed vice dean ... will join Drexel from The Commonwealth Medical College, where she ... dean for clinical affairs, and professor of medicine. , ... Commonwealth Medical College, Weber had a major role in many ...
(Date:7/25/2014)... News) -- Babies seem to learn even before they,re ... women are 34 weeks pregnant, their unborn babies can ... a familiar nursery rhyme, the researchers report. "The ... in the developing fetus," Charlene Krueger, nursing researcher and ... Nursing, said in a university news release. "This research ...
(Date:7/25/2014)... sent patients to designated cardiac receiving centers dramatically increased ... in Arizona, according to a study published online yesterday ... , "We knew lives would be saved if the ... arrest care and we were able to get cardiac ... done for Level 1 trauma patients," said lead study ...
(Date:7/25/2014)... Parkulture is proud to ... parkour instructor, Jared “JJ” Woods, will be competing on ... Ninja Warrior. The show will premiere on local affiliates ... rerun on the new Esquire Network on Tuesday, July ... has been balancing careers as a professional stuntman for ...
(Date:7/25/2014)... 2014 In today’s technological era, every ... supporting devices. This benefits the organization in various ways. ... attacks which can destroy the confidential information and processes ... and Compliance (EGRC) manage and protect the enterprise from ... cause loss in dollars to the comp may. The ...
Breaking Medicine News(10 mins):Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 3Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6
Other TagsOther Tags